Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

pany's GnRH program include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and reports on Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015  PD-Rx Pharmaceuticals, Inc., a publicly held ... partnered with Dobson Technologies, a fully-integrated outsourced IT ... product. PD-Rx is an Application Service ... States.  Using Dobson Technologies, IaaS solution will allow ... ensure regulatory compliance, and reduce operating expenses.  "The ...
(Date:7/28/2015)... July 28, 2015   Vincari , known for ... has just hired John O,Neil as their ... has over 30 years of diverse and progressive experience ... executive healthcare experience coupled with Vincari,s CMO, Dr. ... Vincari to address the challenges both hospitals and surgeons ...
(Date:7/28/2015)... , July 28, 2015  Leaf Healthcare releases ... pressure ulcers place on the healthcare system . ... threat to modern quality healthcare. Research by the ... for Healthcare Research and Quality shows that pressure ... $11 billion a year. The condition is both ...
Breaking Medicine Technology:PD-Rx Partners With Dobson Technologies 2John O'Neil Joins Vincari as Executive Vice President of Strategy and Business Development 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 2Impact of Pressure Ulcers on Patient Care: Leaf Healthcare Releases White Paper on the Healthcare Burden of Pressure Ulcers 3
(Date:7/28/2015)... ... ... Santa Rosa’s The Press Democrat announced its annual report of the very best facilities in ... Furnas took the top spot as the Best Cosmetic Surgeons in Sonoma County . ... be bestowed such a prestigious title. , The Press Democrat was Santa Rosa’s ...
(Date:7/28/2015)... ... ... Her, a unique women’s wellness and lifestyle event designed to inspire and empower women ... level, announced today an influential line-up of inspiring speakers, including Mallika Chopra, founder of ... County based non-profit that works locally and globally to help girls become leaders in ...
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... and Found, a breakthrough technological invention. It is a wearable personal tracking ... electronic industry reached a record high of $211.3 billion in 2014," says Scott ...
(Date:7/28/2015)... ... July 28, 2015 , ... By 2016, the number of ... to engage with customers on a highly personal basis, increasing customer loyalty. However, capitalizing ... big growth opportunities or lose customers to more nimble competitors. , The Open Mobile ...
(Date:7/28/2015)... ... 28, 2015 , ... Autism is the fastest growing serious ... with the disorder. For these families, identifying and paying for the help they ... That’s where Talk About Curing Autism (TACA), a national non-profit organization dedicated to ...
Breaking Medicine News(10 mins):Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2
... have developed an effective technique that uses gene therapy on ... culture, which could eventually serve as a treatment for this ... published in Blood , the Journal of ... a type of white blood cell of the immune system, ...
... common in Germany compared with the rest of Europe. Extensive ... in 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue ... Arztebl Int 2011; 108[15]; 249-54). A woman,s folic acid ... does not develop the neural tube defect commonly known as ...
... The largest study of its type has found that ... drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver ... in the April 27, 2011 issue of Journal of ... in patients with a severe type of fatty liver disease, ...
... oncologist practiced were two factors that strongly influenced the choice ... to an article published April 29 online in the ... IMRT and the cost of radiation therapy increased sharply over ... delivery technique that modulates the radiation beams to conform to ...
... with the Japanese Bone and Mineral Research Society, invite ... bone research to attend the year,s most important bone ... Gold Coast in Queensland, Australia, the congress will present ... on the latest advances in the clinical management of ...
... , THURSDAY, April 28 (HealthDay News) -- ... may already know: the illness can greatly diminish quality of ... took part in the national Behavioral Risk Factor Surveillance ... health was reported by 27 percent of respondents with arthritis ...
Cached Medicine News:Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 2Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 3Health News:JAMA study reports on fatty liver disease in children and teens 2Health News:Use of costly breast cancer therapy strongly influenced by reimbursement policy 2Health News:Preliminary program announced for 2nd Asia-Pacific Osteoporosis & Bone Meeting 2Health News:Study Highlights Arthritis' Toll on Quality of Life 2
... Traditionally, when choosing a non-contact diagnostic lens, doctors ... field of view and high magnification. Now, ... by Volk Optical, doctors can have both in ... field of view available in a non-contact lens ...
... The Stryker BioZip Suture Anchor is a unique ... The BioZip is made from Poly-L Lactic Acid ... 6.5mm. Needles are attached to the suture ends ... for arthroscopic repairs. The trocar tip inserter allows ...
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
Medicine Products: